Phase 3 trials

Mereo BioPharma faces class action lawsuit alleging misrepresentations regarding failed Phase 3 clinical trials, with lead plaintiff deadline April 6, 2026.

ACT Capital Management invests $7.25M in Viking Therapeutics, backing its obesity treatment candidate VK2735 showing 14.7% weight reduction in Phase 2 trials.

Olema reported strong trial progress for palazestrant in breast cancer, raised $218.5M, and expects pivotal data in fall 2026.

EyePoint grants stock options to six new employees as clinical program advances toward Phase 3 topline data for wet AMD therapy.

Parkman Healthcare Partners invests $20M in EyePoint Pharmaceuticals as shares surge 93% annually ahead of mid-2026 Phase 3 data for retinal disease treatment DURAVYU.

Rosen Law Firm urges MREO investors to join class action over alleged misleading statements regarding setrusumab Phase 3 trial failures.

Class action lawsuit filed against Mereo BioPharma over alleged misstatements regarding failed Phase 3 clinical trials. Investors have until April 6, 2026, to join.

AstraZeneca has exclusive access to Abivax data until March 23. If it misses deadline, Eli Lilly could rejoin bidding for French biotech valued by 1,600% surge.

Mereo BioPharma faces class action over failed Phase 3 trials and alleged misleading statements. Investor deadline April 6, 2026.

BioNTech shares plunge 14% as co-founders announce exit plan, with company cutting 2026 revenue guidance due to declining COVID demand.

Class action filed against Mereo BioPharma over allegedly false statements regarding failed Phase 3 clinical trials, covering $MREO investors from June 2023 to December 2025.

Upstream Bio presented additional Phase 2 data for verekitug in chronic rhinosinusitis with nasal polyps, meeting primary endpoints with significant surgical intervention reduction.

Celldex presented Phase 2 data showing barzolvolimab retreatment achieves 62% and 60% complete response rates in cold urticaria and symptomatic dermographism patients.

Five biotech firms advance psychedelic therapies to Phase 3 trials for depression and anxiety, with multiple readouts expected in 2026, marking progress toward regulatory approval.

Psilocybin gains regulatory momentum with first Phase 3 success in treatment-resistant depression. DEA increases production quota 67%, while five pharma companies advance psychedelic programs across multiple CNS indications.

Viking Therapeutics surged 10.91% after Novo Nordisk's obesity drug failed against Eli Lilly's competitor. Viking's dual injectable/oral candidate VK2735 offers differentiation entering Phase 3 trials.

Mereo BioPharma faces class action lawsuit over allegedly false statements regarding failed Phase 3 clinical trials. Investors who bought securities between June 2023-December 2025 may be eligible to participate.

Mereo BioPharma faces class action lawsuit over allegedly misleading disclosures about failed Phase 3 clinical trials. Investors who purchased shares between June 2023 and December 2025 may be eligible.

Viking Therapeutics advances obesity drug VK2735 through phase 3 trials, expecting 2026 trial data. Dual GIP/GLP-1 agonist targets $100B+ market opportunity.

European regulators approve GSK's Exdensur, a biannual asthma injection targeting type 2 inflammation. The drug also treats chronic rhinosinusitis with nasal polyps, showing significant exacerbation reductions in trials.